NASDAQ$OVID
Ovid Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Ovid reshaped the organization to reduce personnel and increase efficiency, advanced its epilepsy pipeline, and prepared OV329 for clinical trials.
Ovid Therapeutics reported its Q4 and full-year 2021 financial results, highlighting a strategic focus on building a leading epilepsy pipeline. The company is advancing OV329 to clinical trials and anticipates Phase 3 results for soticlestat in 2023. Ovid has reshaped its organization to reduce personnel by 20% and improve operational efficiency, extending its cash runway beyond 2024.
- Ovid is focused on building a leading epilepsy pipeline.
- OV329 is expected to enter the clinic in 2022.
- The organization was reshaped to reduce personnel by 20% and increase operational efficiency.
- Targeted business development continues to support the pipeline.
Headline financials
Revenue & EPS history
Ovid Therapeutics · Revenue · Quarterly
-$416M
Revenue by segment
Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020
- License and other revenue$5.7M—100.0%
Forward guidance
Ovid is focused on advancing its epilepsy pipeline, reducing operating expenditures, and pursuing disciplined business development transactions.
Tailwinds
- Advancing a pipeline with novel mechanisms of action for epilepsy therapies.
- On track to initiate a clinical trial this year for OV329.
- Takeda is expected to present pivotal Phase 3 results on soticlestat in 2023.
- Organizational changes ensure a focused team and substantial cash runway.
- Exploring additional business development activities, including securing other compounds and out-licensing non-core programs.
Headwinds
- Uncertainties inherent in the preclinical and clinical development and regulatory approval processes.
- Risks related to Ovid’s ability to achieve its financial objectives.
- The risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy.
- Risks related to Ovid’s ability to identify acquisition targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any strategic transactions or acquisitions
- Risks to Ovid's or any of its collaboration partners’ abilities to meet anticipated deadlines and milestones presented by the ongoing COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+3.6%
Avg return
30 days after
43%
15 / 35 earnings
Positive
+19.5%
Q2 2024
Best reaction
-26.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.9% | -5.7% | — | |
| Q4 2025 | +14.4% | +26.9% | +44.8% | |
| Q3 2025 | -2.2% | -3.7% | +21.5% | |
| Q1 2025 | -0.7% | -6.2% | -8.2% | |
| Q4 2024 | +0.1% | -11.4% | -48.0% | |
| Q2 2024 | +19.5% | +33.7% | +31.4% | |
| Q1 2024 | +9.9% | +4.3% | +6.0% | |
| Q4 2023 | -7.3% | -11.0% | +2.5% | |
| Q3 2023 | -7.9% | -4.8% | -9.5% | |
| Q2 2023 | -1.8% | -0.6% | +6.6% | |
| Q1 2023 | -5.2% | -2.5% | +0.1% | |
| Q4 2022 | +4.0% | +13.0% | +46.0% | |
| Q3 2022 | +2.1% | +11.1% | +26.4% | |
| Q2 2022 | +0.5% | +2.3% | -1.4% | |
| Q1 2022 | -12.1% | -22.3% | -30.5% | |
| Q4 2021 | -3.4% | +0.3% | +0.3% | |
| Q3 2021 | -2.8% | +0.8% | -9.7% | |
| Q2 2021 | -9.4% | -13.1% | -14.4% | |
| Q1 2021 | +2.3% | +6.9% | +28.4% | |
| Q4 2020 | +4.4% | +9.0% | -6.1% | |
| Q3 2020 | +18.9% | +19.1% | -49.6% | |
| Q2 2020 | -2.4% | +4.3% | -20.4% | |
| Q1 2020 | -0.3% | +10.6% | +43.7% | |
| Q4 2019 | -26.9% | -31.5% | -7.8% | |
| Q3 2019 | -1.5% | -6.5% | +54.2% | |
| Q2 2019 | -2.1% | -5.2% | +11.9% | |
| Q1 2019 | -14.0% | -20.1% | -24.8% | |
| Q4 2018 | -2.0% | +1.0% | -6.1% | |
| Q3 2018 | -8.0% | -7.9% | -39.1% | |
| Q2 2018 | +2.3% | +8.8% | -0.2% | |
| Q1 2018 | +4.8% | -1.9% | -9.5% | |
| Q4 2017 | -13.1% | -11.4% | +35.7% | |
| Q3 2017 | +15.2% | +20.4% | +49.7% | |
| Q2 2017 | -1.6% | +2.8% | +28.0% | |
| Q1 2017 | +5.3% | +0.4% | -29.7% | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro